Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare adenocarcinoma of the fallopian tube composed of malignant glandular epithelium containing clear cells.
Biomarker and diagnostic research for fallopian tube clear cell adenocarcinoma has been reported in the published literature.
12 clinical trials registered, 1 recruiting. Interventions under study include procedural interventions, drug therapy, biologic therapy, and other interventions. Pipeline includes 3 PHASE3, 6 PHASE2, 3 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06639074](https://clinicaltrials.gov/study/NCT06639074) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 8:03 PM UTC
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial |
PHASE2 |
Mayo Clinic |
RECRUITING |
21 publications have been identified in PubMed for fallopian tube clear cell adenocarcinoma. Research spans Case Report / Case Series (52%), Clinical Trial Publication (24%), and Basic Science / Preclinical (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 52% |
Clinical study results | 5 | 24% |
Laboratory research | 2 | 10% |
Testing and diagnosis research | 1 | 5% |
Research summaries | 1 | 5% |
Disease patterns and progression | 1 | 5% |
Fukuda N (2026). [PMID: 41430003](https://pubmed.ncbi.nlm.nih.gov/41430003/). *International journal of clinical oncology*. [Clinical Trial Publication]
Jorgensen A (2026). [PMID: 41804072](https://pubmed.ncbi.nlm.nih.gov/41804072/). *Advanced biology*. [Basic Science / Preclinical]
Scott CL (2026). [PMID: 41786760](https://pubmed.ncbi.nlm.nih.gov/41786760/). *Nature reviews. Disease primers*. [Clinical Trial Publication]
Kissinger CR (2026). [PMID: 41593408](https://pubmed.ncbi.nlm.nih.gov/41593408/). *Journal of cancer research and clinical oncology*. [Case Report / Case Series]
Machida H (2025). [PMID: 41129878](https://pubmed.ncbi.nlm.nih.gov/41129878/). *Gynecologic oncology*. [Clinical Trial Publication]
Chui MH (2025). [PMID: 41397226](https://pubmed.ncbi.nlm.nih.gov/41397226/). *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists*. [Clinical Trial Publication]
Li L (2025). [PMID: 40760340](https://pubmed.ncbi.nlm.nih.gov/40760340/). *The journal of pathology. Clinical research*. [Basic Science / Preclinical]
Mardi K (2025). [PMID: 40984937](https://pubmed.ncbi.nlm.nih.gov/40984937/). *Cureus*. [Case Report / Case Series]
Gatta G (2025). [PMID: 40180806](https://pubmed.ncbi.nlm.nih.gov/40180806/). *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. [Epidemiology / Natural History]
Bergaoui H (2025). [PMID: 40188326](https://pubmed.ncbi.nlm.nih.gov/40188326/). *Journal of medical case reports*. [Case Report / Case Series]
AI-curated news mentioning fallopian tube clear cell adenocarcinoma
Updated Mar 4, 2026
A multi-institutional study provides clinical and molecular insights into clear cell adenocarcinoma of the urinary tract. This research enhances understanding of the disease's characteristics, potentially guiding future therapeutic strategies.
A case report highlights primary clear cell adenocarcinoma of the female urethra, a rare disease with limited documented cases. This report contributes to the understanding of this uncommon malignancy.